Impact Biomedicines v. Teva: Consent Judgment in Myelofibrosis Patent Dispute
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Impact Biomedicines, Inc. v. Teva Pharmaceutical Industries, Ltd. |
| Case Number | 2:23-cv-21385 (D.N.J.) |
| Court | U.S. District Court for the District of New Jersey |
| Duration | Oct 2023 – Mar 2024 147 days |
| Outcome | Plaintiff Win — Consent Judgment |
| Patents at Issue | |
| Accused Products | Teva’s generic/biosimilar myelofibrosis treatments |
Case Overview
The Parties
⚖️ Plaintiff
Biopharmaceutical company focused on developing therapies for hematologic malignancies, including myelofibrosis — a rare and serious bone marrow disorder.
🛡️ Defendant
Global technology conglomerate and major generic and specialty pharmaceutical manufacturer, a frequent party in Hatch-Waxman and related infringement proceedings.
Patents at Issue
This case involved two U.S. patents protecting compositions and methods for treating myelofibrosis and related myeloproliferative disorders. Both patents cover therapeutic approaches in this space, an area of active pharmaceutical development involving JAK inhibitors and related small-molecule therapies.
- • U.S. Patent No. 10,391,094 B2 — compositions and methods for treating myelofibrosis
- • U.S. Patent No. 11,400,092 B2 — methods of treating myeloproliferative disorders
Developing a new drug product?
Check if your myelofibrosis therapy might infringe these or related patents before launch.
The Verdict & Legal Analysis
Outcome: Consent Judgment
The case terminated by **consent judgment** — a court-entered order agreed upon by both parties — recorded on March 18, 2024. Specific damages amounts, royalty terms, or injunctive relief provisions were not disclosed in publicly available case records, which is typical of negotiated pharmaceutical patent resolutions where commercial terms remain confidential. For Impact Biomedicines, securing a consent judgment provides enforceable protections against Teva’s continued or future activities with respect to the accused products or methods.
Verdict Cause Analysis
The case was designated an **infringement action**, meaning Impact Biomedicines affirmatively alleged that Teva’s activities infringed one or both of the asserted patents. The swift resolution at 147 days strongly suggests that settlement negotiations were either underway at or shortly after filing, or that the parties reached agreement on infringement parameters without prolonged claim construction or summary judgment proceedings. The dual assertion of composition and method-of-treatment claims likely contributed to this speed of resolution.
Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in myelofibrosis drug development. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this pharmaceutical litigation.
- View all related patents in this therapeutic space
- See which companies are most active in myelofibrosis IP
- Understand claim construction patterns for method patents
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own drug product or therapeutic method.
- Input your drug description or therapeutic features
- AI identifies potentially blocking pharmaceutical patents
- Get actionable risk assessment report
High Risk Area
Myelofibrosis treatment methods
2 Patents Asserted
Composition & Method Claims
Strategic Resolution
Consent judgment in 147 days
✅ Key Takeaways
Consent judgments in pharmaceutical cases carry court-order enforcement weight — a stronger resolution tool than voluntary dismissal.
Search related case law →Dual assertion of composition and method-of-treatment patents creates multi-layered infringement exposure that accelerates settlement.
Explore precedents →District of New Jersey remains the preferred venue for pharmaceutical patent enforcement actions due to its expertise.
View venue insights →Frequently Asked Questions
Two U.S. patents were asserted: U.S. Patent No. 10,391,094 B2 (compositions and methods for treating myelofibrosis) and U.S. Patent No. 11,400,092 B2 (methods of treating myeloproliferative disorders).
The case was an infringement action resolved by mutual agreement of the parties, resulting in a court-entered consent judgment on March 18, 2024. Specific terms were not publicly disclosed.
The case reinforces the enforceability of method-of-treatment patents in the myeloproliferative space and signals that layered patent portfolios can produce swift, binding resolutions against generic pharmaceutical manufacturers.
Ready to Strengthen Your Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- PACER — Case No. 2:23-cv-21385, D.N.J.
- USPTO Patent Center
- Cornell Legal Information Institute — 35 U.S.C.
- PatSnap — IP Intelligence Solutions for Pharma & Biotech
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.